Partnerships for the Development of Tools to Advance Therapeutic Discovery for Select Antimicrobial-Resistant Gram-Negative Bacteria (R01)

Funding Agency:
National Institutes of Health

The purpose of this Funding Opportunity Announcement (FOA) is to support milestone-driven projects focused on developing and utilizing novel predictive assays, models and/or research tools based on penetration and efflux of small molecules to facilitate therapeutic discovery for select Gram-negative bacterial pathogens: carbapenem-resistant Enterobacteriaceae (CRE), MDR Acinetobacter and/or MDR Pseudomonas aeruginosa.  


  • Letter of Intent Due Date(s): April 17, 2017  
  • Application Due Date(s): May 17, 2017 

RFA-AI-16-081 Expiration Date May 18, 2017

Agency Website

Amount Description

Budgets for direct costs of up to $750,000 per year may be requested. Applicants may also request up to an additional $300,000 in the first year of the award for major equipment to ensure that research objectives can be met and biohazards can be contained, totaling $1,050,000 direct costs.

The scope of the proposed project should determine the project period. The maximum project period is 5 years.  

Funding Type





Engineering and Physical Sciences
Medical - Translational

External Deadline

May 17, 2017